Literature DB >> 111595

Amino acid deficiency and the skin rash associated with glucagonoma.

J A Norton, C R Kahn, R Schiebinger, C Gorschboth, M F Brennan.   

Abstract

A 47-year-old white man had a malignant glucagonoma and severe necrolytic migratory erythema. His plasma glucagon levels were markedly elevated at 50 ng/mL and plasma amino acids diminished to 45% of normal. To test the hypothesis that the skin rash associated with a glucagonoma is secondary to an amino acid deficiency, we obtained 2 d of fasting baseline laboratory data from the patient while he consumed his usual diet. He was then given 3 L/d of supplemental intravenous amino acids for 3 d. His plasma amino acid levels increased slightly, and there was some improvement in his skin rash. Immediately thereafter, total parenteral nutrition was administered for 3 d without added zinc or fatty acids. During total parenteral nutrition, 14 of 17 plasma amino acids became normal, and the patient's skin rash rapidly disappeared. These findings suggest that the skin rash associated with a glucagonoma is most likely due to an amino acid deficiency and can be reversed by parenteral nutrition.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111595     DOI: 10.7326/0003-4819-91-2-213

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  Abdominal mass, anemia, diabetes mellitus, and necrolytic migratory erythema.

Authors:  Motaz Qadan; Brendan Visser; Jinah Kim; Reetesh Pai; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-11-17       Impact factor: 3.199

2.  Cutaneous manifestations of methylmalonic acidemia.

Authors:  R J Koopman; R Happle
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.

Authors:  Nicolai J Wewer Albrechtsen; Kristine Færch; Troels M Jensen; Daniel R Witte; Jens Pedersen; Yuvaraj Mahendran; Anna E Jonsson; Katrine D Galsgaard; Marie Winther-Sørensen; Signe S Torekov; Torsten Lauritzen; Oluf Pedersen; Filip K Knop; Torben Hansen; Marit E Jørgensen; Dorte Vistisen; Jens J Holst
Journal:  Diabetologia       Date:  2018-01-05       Impact factor: 10.122

4.  Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.

Authors:  Jeffrey A Norton; Edmund J Harris; Yijun Chen; Brendan C Visser; George A Poultsides; Pamela C Kunz; George A Fisher; Robert T Jensen
Journal:  Arch Surg       Date:  2011-06

5.  Is glucagonoma of the pancreas a curable disease?

Authors:  Q D Chu; M F Al-kasspooles; J L Smith; H R Nava; H O Douglass; D Driscoll; J F Gibbs
Journal:  Int J Pancreatol       Date:  2001

6.  Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.

Authors:  Young Lee; May-Yun Wang; Xiu Quan Du; Maureen J Charron; Roger H Unger
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

7.  Late gestation fetal hyperglucagonaemia impairs placental function and results in diminished fetal protein accretion and decreased fetal growth.

Authors:  Sarah N Cilvik; Stephanie R Wesolowski; Russ V Anthony; Laura D Brown; Paul J Rozance
Journal:  J Physiol       Date:  2021-05-10       Impact factor: 6.228

8.  Atypical necrolytic migratory erythema in association with a jejunal adenocarcinoma.

Authors:  N P Walker
Journal:  J R Soc Med       Date:  1982-02       Impact factor: 18.000

9.  Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.

Authors:  Hameem I Kawsar; Alma Habib; Azhar Saeed; Anwaar Saeed
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.